SG49008A1 - Hla-a2.1 binding peptides and their uses - Google Patents

Hla-a2.1 binding peptides and their uses

Info

Publication number
SG49008A1
SG49008A1 SG1996005140A SG1996005140A SG49008A1 SG 49008 A1 SG49008 A1 SG 49008A1 SG 1996005140 A SG1996005140 A SG 1996005140A SG 1996005140 A SG1996005140 A SG 1996005140A SG 49008 A1 SG49008 A1 SG 49008A1
Authority
SG
Singapore
Prior art keywords
hla
binding peptides
peptides
allele
immunogenic
Prior art date
Application number
SG1996005140A
Other languages
English (en)
Inventor
Howard M Grey
Allessandro Sette
John Sidney
W Martin Kast
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of SG49008A1 publication Critical patent/SG49008A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Confectionery (AREA)
SG1996005140A 1993-03-05 1994-03-04 Hla-a2.1 binding peptides and their uses SG49008A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2714693A 1993-03-05 1993-03-05
US7320593A 1993-06-04 1993-06-04
US15918493A 1993-11-29 1993-11-29

Publications (1)

Publication Number Publication Date
SG49008A1 true SG49008A1 (en) 1998-05-18

Family

ID=27362951

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996005140A SG49008A1 (en) 1993-03-05 1994-03-04 Hla-a2.1 binding peptides and their uses

Country Status (12)

Country Link
EP (1) EP0703783B1 (fr)
JP (1) JP3908271B2 (fr)
KR (1) KR960700739A (fr)
CN (1) CN1118572A (fr)
AT (1) ATE466869T1 (fr)
AU (2) AU6359494A (fr)
BR (1) BR9406652A (fr)
CA (1) CA2157510A1 (fr)
DE (1) DE69435292D1 (fr)
NZ (1) NZ263050A (fr)
SG (1) SG49008A1 (fr)
WO (1) WO1994020127A1 (fr)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
WO1995003777A1 (fr) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides permettant d'induire des reponses des lymphocytes t cytotoxiques au virus de l'hepatite b
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
ATE359089T1 (de) * 1993-02-26 2007-05-15 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
AU685521B2 (en) * 1993-10-19 1998-01-22 Ajinomoto Co., Inc. Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
JPH10503473A (ja) * 1994-04-08 1998-03-31 アメリカ合衆国 細胞傷害性ｔリンパ球刺激およびｈｃｖ曝露診断用ｃ型肝炎ウイルスコアペプチド
US5935797A (en) * 1994-06-16 1999-08-10 Stanford University Interaction of MHC Class II proteins with members of the PCNA family of proteins
SE9403526D0 (sv) 1994-10-14 1994-10-14 Astra Ab New Peptides
EP0793501A4 (fr) * 1994-12-14 2000-05-03 Scripps Research Inst Activation in vivo de lymphocytes t cytotoxiques specifiques de tumeurs
DE69617396T2 (de) * 1995-01-16 2002-09-05 Northern Sydney Area Health Service, St. Leonards T-Zellen beeinflussende Peptide
GB9501300D0 (en) * 1995-01-24 1995-03-15 Boughton Brian J Peptides which inhibit viruses
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
SE9501067D0 (sv) 1995-03-24 1995-03-24 Astra Ab New peptides
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6140464A (en) * 1995-06-07 2000-10-31 Ludwig Institute For Cancer Research Nonapeptides that bind a HLA-A2.1 molecule
US5858972A (en) * 1996-01-11 1999-01-12 La Jolla Cancer Research Foundation Antithrombotic agents and methods of use
CA2242878C (fr) * 1996-01-24 2010-06-22 Cytel Corporation Induction d'une reaction immune contre des determinants souhaites
US5723579A (en) * 1996-02-02 1998-03-03 Bayer Corporation Fibrinogen binding peptides
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
US7001600B1 (en) 1996-02-09 2006-02-21 The United States Of America As Represented By The Secretary Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
DE69733352T2 (de) * 1996-03-21 2006-04-27 Epimmune, Inc., San Diego Hla-a2.1 bindende peptide und deren verwendung
EP1767542B1 (fr) * 1996-03-21 2016-05-11 Epimmune Inc. Peptides de fixation de HLA-A2.1 et leurs utilisation
CA2257973C (fr) 1996-06-11 2010-02-02 Northern Sydney Area Health Services Peptides recepteurs d'antigene des cellules t
US6465251B1 (en) 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
DE69837666T2 (de) * 1997-08-01 2007-12-27 Genetic Systems Corp., Redmond Synthetische antigene zum nachweis von antikörpern mit immunreaktivität gegen hiv-virus
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
DE69820486D1 (de) * 1998-01-19 2004-01-22 Mogam Biotechnology Res Inst Y Liposomen, enthaltend peptidantigene, welche vom x-protein aus hepatitis b virus abstammen
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
WO1999040930A1 (fr) * 1998-02-12 1999-08-19 Center For Blood Research, Inc. Inhibiteurs specifiques d'activation des proteines nfat par la calcineurine, et utilisation dans le traitement des maladies liees a l'immunisation
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
EP0955311A3 (fr) * 1998-04-09 2000-08-16 Idexx Laboratories, Inc. Vaccin peptidique contre l'allergie des chiens
EP1089757B1 (fr) * 1998-06-17 2009-04-22 IDM Pharma, Inc. Peptides liant hla-a2 et leurs utilisations
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
ATE370234T1 (de) * 1998-09-01 2007-09-15 Us Gov Health & Human Serv Page-4, ein gage-ähnliches gen auf dem x- chromosom das von neoplastischer prostata, testis und uterus exprimiert wird, und dessen anwendungen
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
WO2000058365A1 (fr) * 1999-03-30 2000-10-05 Idexx Laboratories, Inc. Proteines de liaison specifiques pour le traitement d'allergies
EP1082340A1 (fr) * 1999-03-30 2001-03-14 Idexx Laboratories, Inc. Vaccin peptidique pour allergie canine
EP1176986B1 (fr) 1999-04-20 2018-07-04 Yale University Differentiation de monocytes transformes en cellules dendritiques fonctionnelles
JP2003535024A (ja) * 1999-06-29 2003-11-25 エピミューン インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの使用
US7129052B1 (en) * 2000-07-12 2006-10-31 The United States Of America As Represented By The Department Of Health And Human Services Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO2001036452A2 (fr) * 1999-11-18 2001-05-25 Epimmune Inc. Analogues heteroclites et procedes associes
ATE298346T1 (de) 1999-12-06 2005-07-15 Chu Sainte Justine Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2001041741A1 (fr) * 1999-12-13 2001-06-14 Epimmune Inc. Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2400215A1 (fr) * 2000-02-23 2001-08-30 Epimmune Inc. Peptides de liaison hla et utilisations de ces derniers
CA2413211A1 (fr) 2000-04-04 2001-10-11 University Of Rochester Gene exprime de maniere differentielle dans le cancer du sein et de la vessie et polypeptides codes
DK1292321T3 (da) * 2000-05-12 2012-01-30 Northwest Biotherapeutics Inc Fremgangsmåde til at forøge klasse 1 præsentation af exogene antigener gennem humane dendritiske celler
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
ES2311540T3 (es) 2000-08-28 2009-02-16 Agensys, Inc. Acido nucleico y proteina correspondiente llamada 85p1b3 util en el tratamiento y deteccion del cancer.
EP1343819A4 (fr) * 2000-09-01 2005-03-23 Epimmune Inc Peptides de fixation de hla-a2.1 et leurs utilisations
EP1195381A1 (fr) 2000-09-28 2002-04-10 Immusystems GmbH Epitopes du virus de l'hépatite C spécifiques à des lymphocytes T de type CD4+
CA2425648A1 (fr) 2000-10-19 2002-04-19 Epimmune Inc. Peptides de liaison aux hla de classe i et ii et leurs utilisations
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002077012A2 (fr) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptides immunoreactifs du papillomavirus humain
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
EP2280030A3 (fr) 2001-04-10 2011-06-15 Agensys, Inc. Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
JP2005500058A (ja) 2001-08-17 2005-01-06 ネオーズ テクノロジーズ， インコーポレイテッド シアリル化したオリゴサッカリドの化学的酵素的合成
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
WO2003104428A2 (fr) 2002-01-21 2003-12-18 Vaccinex, Inc. Gene s'exprimant de façon differentielle dans le cancer du sein et de la vessie et polypeptides codes
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
CA2484941A1 (fr) 2002-07-24 2004-02-05 Intercell Ag Antigenes a phase de lecture alternante a partir de virus
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20040180354A1 (en) * 2002-09-06 2004-09-16 Simard John J.L. Epitope sequences
WO2004024182A2 (fr) 2002-09-13 2004-03-25 Intercell Ag Procede pour isoler des peptides du virus de l'hepatite c
US20060079453A1 (en) 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
EP1903056A3 (fr) 2002-12-10 2008-05-07 Idm Pharma, Inc. Peptides se liant au HLA-A1, -A2, -A3, -A24, -B7 and -B44 et comprenant des épitopes d'antigène associé à une tumeur, et compositions les comprenant
WO2004058807A2 (fr) * 2002-12-24 2004-07-15 Algonomics N.V. Peptides de stimulation de lymphocytes t a restreint par des molecules de classe i provenant du virus de l'hepatite b
EP2343315A3 (fr) 2003-02-10 2011-11-23 Agensys, Inc. Acide nucléique et protéine correspondante appelée 158P1D7 utile pour le traitement et la détection de cancer de la vessie et autres
PL211458B1 (pl) 2003-02-14 2012-05-31 Provid Pharmaceuticals Związki, kompozycja farmaceutyczna zawierająca je oraz zastosowanie związków
ES2562456T3 (es) 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
WO2004092207A2 (fr) * 2003-04-16 2004-10-28 Algonomics N.V. Peptides du virus respiratoire syncytial (rsv)
ES2456666T3 (es) 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
KR101291787B1 (ko) 2003-05-30 2013-08-07 어젠시스 인코포레이티드 전립선 줄기 세포 항원 (ｐｓｃａ) 변이체 및 그의서브서열
CA2530062A1 (fr) 2003-07-11 2005-01-20 Intercell Ag Vaccins contre le virus de l'hepatite c
JPWO2005007694A1 (ja) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド ＨＥＲ２／ｎｅｕペプチドおよびその治療上の用途
KR20060087574A (ko) * 2003-09-22 2006-08-02 가부시키가이샤 그린 펩티드 Ｃ형 간염 바이러스 유래 펩티드
US7348007B2 (en) * 2004-02-09 2008-03-25 Ludwig Institute For Cancer Research Mage C2 antigenic peptides and uses thereof
CN1954068B (zh) * 2004-04-30 2011-03-02 日本电气株式会社 Hla-结合肽，其前体，编码这些肽序列的dna片段和重组载体
EP2428522A1 (fr) 2004-05-28 2012-03-14 Agensys, Inc. Anticorps se liant à des protéines PSCA pour le diagnostic du cancer
KR100790646B1 (ko) * 2004-07-03 2008-01-02 재단법인 목암생명공학연구소 세포매개 면역반응을 효과적으로 유도하는 ｈｃｖ수퍼타입 에피토프, 그를 코딩하는 올리고뉴클레오타이드및 그의 용도
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
FR2887884B1 (fr) * 2005-06-29 2007-09-14 Pasteur Institut Epitopes de la proteine hbsp et leurs applications biotechnologiques et medicales, notamment pour le traitement de l'hepatite b chronique
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CA2622036A1 (fr) * 2005-09-08 2007-03-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, In C. Identification ciblee de peptides immunogenes
US20090023895A1 (en) 2006-02-07 2009-01-22 Nec Corporation Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide
EP2434014B1 (fr) 2006-10-12 2014-12-10 Nec Corporation Peptide liant les molécules HLA et son précurseur; fragment d'ADN et vecteur recombinant encodant ceux-ci
EP2215111B1 (fr) 2007-11-01 2016-03-16 Mayo Foundation For Medical Education And Research Peptides de liaison hla-dr et leurs utilisations
DE102007059924A1 (de) * 2007-12-03 2009-06-04 Eberhard-Karls-Universität Tübingen Universitätsklinikum Allel- und Isotyp-spezifische Intervention an mit Autoimmunerkrankungen assoziierten MHC-Klasse-II-Molekülen durch Peptide
EP2234632B1 (fr) * 2008-01-10 2014-10-29 Endocrine Pharmaceuticals Limited Composés protéinés
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
WO2011064779A2 (fr) * 2009-11-29 2011-06-03 Yeda Research And Development Co. Ltd. Peptides dérivés du domaine transmembranaire de la protéine gp41 du vih-1 et leurs procédés d'utilisation
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CR20180519A (es) 2016-03-31 2019-03-05 Neon Therapeutics Inc Neoantígenos y métodos de su uso
EP3475706B1 (fr) 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Épitopes restreints au cmh-e, molécules de liaison, et procédés et utilisations associés
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
JP7457642B2 (ja) 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
WO2019094642A1 (fr) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. Compositions et procédés de production de lymphocytes t
WO2019246286A1 (fr) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Néoantigènes et leurs utilisations
WO2020037239A1 (fr) 2018-08-16 2020-02-20 Neon Therapeutics, Inc. Constructions de récepteurs de cellules t et leurs utilisations
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
US12247053B2 (en) 2018-10-26 2025-03-11 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
WO2020252039A1 (fr) 2019-06-12 2020-12-17 Biontech Us Inc. Compositions de néoantigènes et utilisations associées
CN115974985A (zh) * 2019-12-13 2023-04-18 南京大户生物科技有限公司 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
WO2022036142A2 (fr) 2020-08-13 2022-02-17 Biontech Us Inc. Néoantigènes ras et leurs utilisations
IL300564A (en) 2020-08-13 2023-04-01 Biontech Us Inc Preparations and methods for the production of T cells
CA3202176A1 (fr) 2020-12-14 2022-06-23 Michael Steven ROONEY Antigenes specifiques de tissu pour une immunotherapie anticancereuse
AU2022350653A1 (en) 2021-09-22 2024-05-02 BioNTech SE Coronavirus vaccines and methods of use
US20240366754A1 (en) 2021-10-15 2024-11-07 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
EP4469063A1 (fr) 2022-01-27 2024-12-04 BioNTech SE Compositions pharmaceutiques pour administration d'antigènes du virus herpès simplex et méthodes associées
CN114591404B (zh) * 2022-03-23 2024-12-10 成都朗谷生物科技股份有限公司 适用于白细胞抗原单倍型为hla-a2个体的乙型肝炎病毒抗原肽及其应用
CN115960858B (zh) * 2022-08-24 2025-03-25 山东大学齐鲁医院 一种乙肝病毒特异性的肽段以及四聚体与检测乙肝病毒特异性cd8+t细胞的试剂盒
WO2024157221A1 (fr) 2023-01-27 2024-08-02 BioNTech SE Compositions pharmaceutiques pour administration d'antigènes de glycoprotéine c, de glycoprotéine d et de glycoprotéine e du virus de l'herpès simplex et procédés associés
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
EP4669348A1 (fr) 2023-02-24 2025-12-31 BioNTech SE Compositions immunogènes
IL326358A (en) 2023-08-03 2026-04-01 Univ Pennsylvania RNA compositions encoding herpes simplex virus glycoprotein E and/or glycoprotein I antigens and their uses
WO2025030165A1 (fr) 2023-08-03 2025-02-06 BioNTech SE Compositions pharmaceutiques pour l'administration d'antigènes du virus de l'herpès simplex et procédés associés
AU2024316992A1 (en) 2023-08-03 2026-03-12 BioNTech SE Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
WO2025030154A1 (fr) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Compositions pharmaceutiques pour l'administration d'antigènes de glycoprotéine b du virus herpès simplex et méthodes associées
CN121772938A (zh) 2023-08-03 2026-03-31 百欧恩泰欧洲股份公司 用于递送单纯疱疹病毒抗原的药物组合物及相关方法
WO2025106738A1 (fr) 2023-11-15 2025-05-22 BioNTech SE Compositions immunogènes de sars-cov-2
WO2025219955A1 (fr) 2024-04-17 2025-10-23 BioNTech SE Tcr solubles et leurs méthodes d'utilisation
WO2025224684A1 (fr) 2024-04-24 2025-10-30 BioNTech SE Compositions et procédés de production de cellules immunitaires modifiées
WO2025255393A1 (fr) 2024-06-06 2025-12-11 The Trustees Of The University Of Pennsylvania Agents de liaison à l'antigène du virus de l'herpès simplex pour atténuer une maladie associée au virus de l'herpès simplex
WO2026015882A1 (fr) 2024-07-12 2026-01-15 BioNTech SE Fragments d'antigène hsv et procédés associés
WO2026047601A1 (fr) 2024-08-28 2026-03-05 BioNTech SE Récepteurs de lymphocytes t (tcr)
WO2026047603A1 (fr) 2024-08-28 2026-03-05 BioNTech SE Compositions immunogènes contre sars-cov-2
WO2026058153A2 (fr) 2024-09-10 2026-03-19 BioNTech SE Utilisations de récepteur de lymphocytes t de vph-16 et compositions associées

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
IL109664A0 (en) * 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor

Also Published As

Publication number Publication date
AU6359494A (en) 1994-09-26
BR9406652A (pt) 1996-09-10
EP0703783A1 (fr) 1996-04-03
CA2157510A1 (fr) 1994-09-15
KR960700739A (ko) 1996-02-24
NZ263050A (en) 1997-11-24
AU6597998A (en) 1998-07-02
ATE466869T1 (de) 2010-05-15
EP0703783A4 (fr) 1999-03-10
JPH08507525A (ja) 1996-08-13
WO1994020127A1 (fr) 1994-09-15
EP0703783B1 (fr) 2010-05-05
WO1994020127A9 (fr) 2003-04-17
DE69435292D1 (de) 2010-06-17
CN1118572A (zh) 1996-03-13
JP3908271B2 (ja) 2007-04-25

Similar Documents

Publication Publication Date Title
EP0703783A4 (fr) Peptides se liant a hla-a2.1 et leurs utilisations
EP0907370A4 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
IL106610A0 (en) Hla binding peptides and their uses
AU5898400A (en) Hla binding peptides and their uses
AU2001298049A8 (en) Hla class i and ii binding peptides and their uses
GB9624456D0 (en) Assay method
AU6632496A (en) Cell derived antigen presenting vesicles
NZ326092A (en) Immunostimulatory composition and method
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
EP0997477A3 (fr) MHC-complexes et leurs applications
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
CA2182889A1 (fr) Peptides reconnus par les lymphocytes cytotoxiques specifiques du melanome, et applications
AU4577899A (en) Hla binding peptides and their uses
AU2000273396A1 (en) Hla binding peptides and their uses
MY102593A (en) Antigents of plasmodium falciparum
PL313257A1 (en) Novel tripeptides useful in treating immune system and central nervous system
WO1999047102A3 (fr) Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes